Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.67 |
| ▸ | MLYCD | O95822 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332754 | 0.93 | MAPK14 (0.61) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4329157 | 0.91 | MAPK14 (0.80) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4330141 | 0.90 | MAPK14 (0.76) | MAPK14MLYCDLMNA | |
| SCHEMBL4346437 | 0.88 | MAPK14 (0.54) | MAPK14MLYCDNOTUMLMNATSHR | |
| SCHEMBL4333445 | 0.87 | MAPK14 (0.59) | MAPK14MLYCDNOTUMTSHR | |
| SCHEMBL4338186 | 0.86 | MAPK14 (0.64) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4348722 | 0.86 | MAPK14 (0.59) | MAPK14MLYCDNOTUMMAPK9MAPK10 | |
| SCHEMBL4335579 | 0.85 | MAPK14 (0.70) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335445 | 0.85 | MAPK14 (0.70) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335639 | 0.85 | MAPK14 (0.63) | MAPK14MLYCDMAPK9MAPK10MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MLYCD 4475/4885NOTUM 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.